Drug Trial Radar · NCT07780383
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Aug 21, 2026
Primary completion
Jun 17, 2027
Study completion Jun 17, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration
Conditions
- Alzheimer's Disease
- Healthy Participants
Interventions
BMS-986446Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous (SC) infusionTime frame: Up to approximately 5 months
- Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusionTime frame: Up to approximately 5 months
- Maximum observed concentration (Cmax)Time frame: Up to approximately 5 months
- Time of maximum observed concentration (Tmax)Time frame: Up to approximately 5 months
- Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to approximately 5 months
- Area under the serum concentration-time curve from time zero to 672 hours (AUC(0-672))Time frame: Up to approximately 5 months
- AUC(INF)Time frame: Up to approximately 5 months
- Half-life (T-HALF)Time frame: Up to approximately 5 months
- Apparent total body clearance in SC administration (CLT/F)Time frame: Up to approximately 5 months
- Total body clearance in IV infusion (CLT)Time frame: Up to approximately 5 months
- Apparent volume of distribution of terminal phase in SC administration (Vz/F)Time frame: Up to approximately 5 months
- Volume of distribution of terminal phase (VZ)Time frame: Up to approximately 5 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
Anaheim, California · Recruiting
Local Institution - 0003
Bradenton, Florida · Not yet recruiting
Local Institution - 0005
Daytona Beach, Florida · Not yet recruiting
Local Institution - 0007
Naples, Florida · Not yet recruiting
Local Institution - 0006
The Villages, Florida · Not yet recruiting
Local Institution - 0004
Decatur, Georgia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.